Abstract
The Tokyo 2020 Olympic Games (Games) were held during the height of the coronavirus disease 2019 (COVID-19) pandemic. In order to detect the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) early enough to contain the spread as well as to facilitate the timely arrival of athletes at their game venues, all participating athletes up to 14,000 staying in the Olympic Village were screened daily for the infection. Toward this aim, a two-step strategy was adopted comprising screening of self-collected saliva samples using a chemiluminescence enzyme immunoassay followed by confirmatory testing using polymerase chain reaction. The testing system was integrated with an information management system covering all steps. To ensure the accuracy of testing results, rigorous quality assurance measures and monitoring of performance/specimen quality were implemented. The chronological chart analysis was implemented to monitor the holistic process and to give feedback to improve the sampling. Nearly all test results for 418506 saliva samples were reported within 12 hours of sample collection, achieving the target mean turnaround time of 150 minutes for confirmatory testing. As a result, athlete activity and performance for the Games were ensured. The chronological chart confirmed that no athletes were retired due to a false-positive result and no infection clusters among athletes were identified. In conclusion, continuous quality improvement in the two-step strategy for the large-scale screening of COVID-19 contributed to the success of the Games during the pandemic. The quality practice, systems, and workflows described here may offer a model for future mass-gathering sporting events during similar major infectious disease epidemics.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: For non-financial conflicts of interest, H.M., S.A., S.S., and C.I. have published several papers about COVID-19 and could have conflicts of interest among healthcare professionals. For financial conflicts of interest, H.M. was a consultant at SRL Laboratories and an adviser for the laboratory in the Olympic and Paralympic Village in Harumi, Tokyo, Japan. H.M. and S.A. were involved in the nationwide external quality assessment of SARS-CoV-2 nucleic acid tests, a project commissioned by the Ministry of Health, Labour and Welfare of Japan. S.A. contributed to studies on SARS-CoV-2 PCR tests developed by DENSO Corp. and KYORIN Pharm. Co., Ltd. that were financially supported by the Japan Agency for Medical Research and Development. R.K. and K.O. rendered laboratory service for athletes and team officials during the Tokyo 2020 Games as a commission project by the Tokyo Organizing Committee of the Olympic and Paralympic Games. S.S. and C. I. worked as staff members for Tokyo 2020 during the Tokyo 2020 Games. The authors report no other potential conflicts of interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical review of the study was judged as waived by the ethics committee of Niobe bunka College.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
sa{at}tokai.ac.jp
rika.kuroki{at}hugp.com
kazuya.omi{at}hugp.com
i-chiaki{at}niid.go.jp
satoshishimada30{at}gmail.com
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
